.jpg)
During the collaboration, we leveraged AbbVie's rich source of historic sales and marketing data to determine the true business impact and return on investment of messaging and channel marketing activities. The overall aim was to maximize the quality and relevance of marketing communications, while reducing the overall level of disruption to busy healthcare professionals.
Daniel, IFT Excellence Manager at AbbVie, shared his thoughts on our collaboration: “Partnering with Fluence on a machine learning initiative helped us uncover the unexplored depths within our data and the extensive scope to enhance our work procedures. The outcomes exceeded our expectations, even enabling us to foresee the impact of specific market activities. This newfound ability allows us to concentrate our efforts on only the most efficient activities when promoting products. The strong impact we have seen in the pilot led us to continue on this promising venture. We are now transitioning from the pilot phase to an expansive implementation, a step that promises to enhance our efficiency and performance even more.” Read what Daniel had to say here.
These outcomes underline the opportunities that emerge when companies make full use of their data assets, translating historic data into impactful communications with the healthcare community.
This project is only the beginning. The investigative framework we have developed provides a practical blueprint for achieving a wide range of strategic objectives. Read more about what AbbVie had to say here.
Heartfelt thanks to our counterparts at AbbVie, and in particular, Dr. Dorothea Werdenberg, MBA and Daniel Imwinkelried, for their continued efforts on the project.
